Vijay Kumar
Stock Analyst at Evercore ISI Group
(3.25)
# 1,053
Out of 5,154 analysts
289
Total ratings
49.15%
Success rate
1.04%
Average return
Main Sectors:
Stocks Rated by Vijay Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CAI Caris Life Sciences | Maintains: Outperform | $38 → $34 | $18.59 | +82.89% | 3 | Feb 27, 2026 | |
| PEN Penumbra | Maintains: Outperform | $340 → $360 | $338.64 | +6.31% | 3 | Feb 26, 2026 | |
| USB U.S. Bancorp | Maintains: In-Line | $60 → $65 | $52.37 | +24.12% | 8 | Feb 5, 2026 | |
| GEHC GE HealthCare Technologies | Maintains: Outperform | $95 → $98 | $74.27 | +31.95% | 6 | Feb 5, 2026 | |
| BSX Boston Scientific | Maintains: Outperform | $112 → $96 | $71.35 | +34.55% | 8 | Feb 5, 2026 | |
| AZTA Azenta | Maintains: Outperform | $50 → $45 | $24.30 | +85.19% | 10 | Feb 5, 2026 | |
| TWST Twist Bioscience | Maintains: Outperform | $42 → $52 | $46.94 | +10.78% | 7 | Feb 3, 2026 | |
| RVTY Revvity | Maintains: Outperform | $112 → $118 | $91.34 | +29.19% | 4 | Feb 3, 2026 | |
| ISRG Intuitive Surgical | Maintains: In-Line | $580 → $550 | $490.16 | +12.21% | 15 | Jan 23, 2026 | |
| ABT Abbott Laboratories | Maintains: Outperform | $144 → $138 | $109.56 | +25.96% | 18 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $168 → $223 | $213.39 | +4.50% | 9 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $79 → $78 | $75.74 | +2.98% | 17 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $105 | $103.50 | +1.45% | 8 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $18 | $17.06 | +5.51% | 12 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $14 → $12 | $8.17 | +46.88% | 13 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $94 → $120 | $94.11 | +27.51% | 15 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $194 → $210 | $123.59 | +69.92% | 3 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $155 → $160 | $115.07 | +39.05% | 8 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $410 → $405 | $364.56 | +11.09% | 13 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $132 → $142 | $124.62 | +13.95% | 9 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $88 → $92 | $81.64 | +12.69% | 15 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $525 → $590 | $501.97 | +17.54% | 13 | Oct 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,275 → $1,400 | $1,209.65 | +15.74% | 12 | Oct 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $226 → $245 | $195.50 | +25.32% | 4 | Oct 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $31 | $17.69 | +75.24% | 8 | Oct 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $103 → $106 | $90.90 | +16.61% | 5 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $46 | $24.51 | +87.68% | 4 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $3 | $3.19 | -5.96% | 6 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $18 → $30 | $13.04 | +130.06% | 11 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $335 → $355 | $302.54 | +17.34% | 8 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $160 | $87.03 | +83.84% | 7 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $286 → $290 | $167.12 | +73.53% | 6 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.07 | +554.21% | 1 | May 31, 2022 |
Caris Life Sciences
Feb 27, 2026
Maintains: Outperform
Price Target: $38 → $34
Current: $18.59
Upside: +82.89%
Penumbra
Feb 26, 2026
Maintains: Outperform
Price Target: $340 → $360
Current: $338.64
Upside: +6.31%
U.S. Bancorp
Feb 5, 2026
Maintains: In-Line
Price Target: $60 → $65
Current: $52.37
Upside: +24.12%
GE HealthCare Technologies
Feb 5, 2026
Maintains: Outperform
Price Target: $95 → $98
Current: $74.27
Upside: +31.95%
Boston Scientific
Feb 5, 2026
Maintains: Outperform
Price Target: $112 → $96
Current: $71.35
Upside: +34.55%
Azenta
Feb 5, 2026
Maintains: Outperform
Price Target: $50 → $45
Current: $24.30
Upside: +85.19%
Twist Bioscience
Feb 3, 2026
Maintains: Outperform
Price Target: $42 → $52
Current: $46.94
Upside: +10.78%
Revvity
Feb 3, 2026
Maintains: Outperform
Price Target: $112 → $118
Current: $91.34
Upside: +29.19%
Intuitive Surgical
Jan 23, 2026
Maintains: In-Line
Price Target: $580 → $550
Current: $490.16
Upside: +12.21%
Abbott Laboratories
Jan 23, 2026
Maintains: Outperform
Price Target: $144 → $138
Current: $109.56
Upside: +25.96%
Jan 13, 2026
Maintains: Outperform
Price Target: $168 → $223
Current: $213.39
Upside: +4.50%
Jan 5, 2026
Downgrades: In-Line
Price Target: $79 → $78
Current: $75.74
Upside: +2.98%
Jan 5, 2026
Downgrades: In-Line
Price Target: $105
Current: $103.50
Upside: +1.45%
Jan 5, 2026
Downgrades: In-Line
Price Target: $18
Current: $17.06
Upside: +5.51%
Jan 5, 2026
Downgrades: In-Line
Price Target: $14 → $12
Current: $8.17
Upside: +46.88%
Jan 5, 2026
Upgrades: Outperform
Price Target: $94 → $120
Current: $94.11
Upside: +27.51%
Jan 5, 2026
Upgrades: Outperform
Price Target: $194 → $210
Current: $123.59
Upside: +69.92%
Jan 5, 2026
Upgrades: Outperform
Price Target: $155 → $160
Current: $115.07
Upside: +39.05%
Oct 31, 2025
Maintains: Outperform
Price Target: $410 → $405
Current: $364.56
Upside: +11.09%
Oct 31, 2025
Maintains: Outperform
Price Target: $132 → $142
Current: $124.62
Upside: +13.95%
Oct 31, 2025
Maintains: Outperform
Price Target: $88 → $92
Current: $81.64
Upside: +12.69%
Oct 7, 2025
Maintains: Outperform
Price Target: $525 → $590
Current: $501.97
Upside: +17.54%
Oct 7, 2025
Maintains: Outperform
Price Target: $1,275 → $1,400
Current: $1,209.65
Upside: +15.74%
Oct 7, 2025
Maintains: Outperform
Price Target: $226 → $245
Current: $195.50
Upside: +25.32%
Oct 7, 2025
Maintains: Outperform
Price Target: $33 → $31
Current: $17.69
Upside: +75.24%
Jul 8, 2025
Maintains: Outperform
Price Target: $103 → $106
Current: $90.90
Upside: +16.61%
Jul 8, 2025
Maintains: Outperform
Price Target: $48 → $46
Current: $24.51
Upside: +87.68%
May 19, 2025
Maintains: In-Line
Price Target: $3
Current: $3.19
Upside: -5.96%
Dec 2, 2024
Upgrades: Outperform
Price Target: $18 → $30
Current: $13.04
Upside: +130.06%
Oct 1, 2024
Maintains: In-Line
Price Target: $335 → $355
Current: $302.54
Upside: +17.34%
Oct 1, 2024
Maintains: Outperform
Price Target: $120 → $160
Current: $87.03
Upside: +83.84%
Oct 1, 2024
Maintains: Outperform
Price Target: $286 → $290
Current: $167.12
Upside: +73.53%
May 31, 2022
Initiates: Outperform
Price Target: $7
Current: $1.07
Upside: +554.21%